Multiple Myeloma Clinical Trials in New York, New York

46 studies are recruiting for multiple myeloma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

   The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Mount Sinai Medical Center, New York, New York

   Locations

   50 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05201781 on ClinicalTrials.gov

2. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

   The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Perlmutter Cancer Center at NYU Langone Health, New York, New York

   Locations

   270 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05552222 on ClinicalTrials.gov

3. A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

   The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilt…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   20 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07149857 on ClinicalTrials.gov

4. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mount Sinai Chelsea, New York, New York

   Locations

   157 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07258511 on ClinicalTrials.gov

5. A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

   The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab, lenalidomide, bortezomib, and dexamethasone) is a safe treatment for people with newly diagnosed multiple myeloma (MM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07099391 on ClinicalTrials.gov

6. AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

   This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, New York, New York

   Locations

   46 in total

   Run by

   AstraZeneca

   See if you can join NCT06106945 on ClinicalTrials.gov

7. A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

   This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The Tisch Cancer Institute/Mount Sinai, New York, New York

   Locations

   60 in total

   Run by

   C4 Therapeutics, Inc.

   See if you can join NCT07284758 on ClinicalTrials.gov

8. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

   Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity. The main purpose of the study is to evaluate if the combination of Elranatamab, Daratumumab and Lenalidomide offers superio…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York, New York

   Locations

   180 in total

   Run by

   Pfizer

   See if you can join NCT05623020 on ClinicalTrials.gov

9. A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

   Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214, New York, New York

   Locations

   51 in total

   Run by

   AbbVie

   See if you can join NCT06953960 on ClinicalTrials.gov

10. Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

    The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research que…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Locations

    40 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT03761108 on ClinicalTrials.gov

11. A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

    A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan-Kettering Cancer Center, New York, New York

    Locations

    29 in total

    Run by

    K36 Therapeutics, Inc.

    See if you can join NCT05651932 on ClinicalTrials.gov

12. A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

    Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapse…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mount Sinai - The Tisch Cancer Institute /ID# 272470, New York, New York

    Locations

    36 in total

    Run by

    AbbVie

    See if you can join NCT06892522 on ClinicalTrials.gov

13. A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. This is a study to determine the adverse events, change…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Icahn School of Medicine at Mount Sinai /ID# 277844, New York, New York

    Locations

    49 in total

    Run by

    AbbVie

    See if you can join NCT07095452 on ClinicalTrials.gov

14. A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

    The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07105059 on ClinicalTrials.gov

15. A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

    The purpose of this study is to collect voice recordings and nervous system (neurologic) assessments from people with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) who are receiving standard treatment with CAR T-cell therapy. Researchers will study whether these voice recordings and assessmen…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York, New York

    Locations

    8 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07249528 on ClinicalTrials.gov

16. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

    This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Mount Sinai Medical Center - 2, New York, New York

    Locations

    212 in total

    Run by

    European Myeloma Network B.V.

    See if you can join NCT05243797 on ClinicalTrials.gov

17. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Locations

    52 in total

    Run by

    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

    See if you can join NCT06297226 on ClinicalTrials.gov

18. A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

    The researchers are going this to look at how butyrate levels change in participants' stool after they are on a plant-based diet or dietary supplements (omega-3, curcumin or probiotics) for 2 weeks. All participants will have smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermine…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06055894 on ClinicalTrials.gov

19. Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

    The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

    Locations

    9 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06976476 on ClinicalTrials.gov

20. A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

    The purpose of this study is to see if siltuximab plus population pharmacokinetic (PK)-dosed melphalan works as well as the usual approach (body surface area [BSA]-dosed melphalan) in people with multiple myeloma (MM) who are receiving an autologous stem cell transplant (ASCT) as part of their stan…

    Stage

    Phase 2

    Ages

    60 and older

    Site

    Memorial Sloan Kettering Cancer Center (All protocol activities), New York, New York

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06679829 on ClinicalTrials.gov

21. A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

    The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste ch…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Icahn School of Medicine at Mt. Sinai, New York, New York

    Locations

    38 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT06500884 on ClinicalTrials.gov

22. A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

    This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, New York, New York

    Locations

    13 in total

    Run by

    AstraZeneca

    See if you can join NCT07073547 on ClinicalTrials.gov

23. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

    This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54~360 subjects, and a phase 2 stage to explore efficacy, safe…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering, New York, New York

    Locations

    6 in total

    Run by

    Fortvita Biologics (USA)Inc.

    See if you can join NCT07336472 on ClinicalTrials.gov

24. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    NYU Langone Health Manhattan, New York, New York

    Locations

    173 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT07518186 on ClinicalTrials.gov

25. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

    Stage

    Phase 2

    Ages

    12 and older

    Site

    Manhattan Eye, Ear, and Throat Hospital, New York, New York

    Locations

    181 in total

    Run by

    American Society of Clinical Oncology

    See if you can join NCT02693535 on ClinicalTrials.gov